Ex vivo response to aspirin differs in stroke patients with single or recurrent events: A pilot study

Journal of the Neurological Sciences

Volumn 171, Issue 2, 1999, Pages 110-114

  Chamorro, Angel ^a   Escolar, Ginés ^b   Revilla, Marian ^a   Obach, Víctor ^a   Vila, Nicolás ^a   Reverter, Juan C ^b   Ordinas, Antonio ^b  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Aspirin; Cerebrovascular disease; Platelets

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADRENALIN; ARACHIDONIC ACID; THROMBOXANE RECEPTOR STIMULATING AGENT;

ADULT; AGED; ARTICLE; CEREBROVASCULAR DISEASE; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; STROKE; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT OUTCOME;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; AGED; ASPIRIN; CEREBROVASCULAR ACCIDENT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PILOT PROJECTS; PLATELET AGGREGATION; PROSPECTIVE STUDIES; RECURRENCE;

EID: 0032700388     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(99)00260-9     Document Type: Article

References (23)

1. Collaborative overview of randomized trials of antiplatelet therapy. 1. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J. 308:1994;81-106.
2. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J. 296:1988;320-331.
3. Algra A., van Gijn J. Aspirin at any dose above 30 mg offers only modest protection after cerebral ischemia. J Neurol Neurosurg Psychiatry. 60:1996;197-199.
4. Hart R.G., Harrison J.G. Aspirin wars. The optimal dose of aspirin to prevent stroke. Stroke. 27:1996;585-587.
5. Dyken M.L. Meta-analysis in the assessment of therapy for stroke prevention. Cerebrovasc Dis. 2:(suppl 1):1991;35-40.
6. Patrono C., Roth G.J. Aspirin in ischemic cerebrovascular disease. How strong is the case for a different dosing regimen? Stroke. 27:1996;756-760.
7. Masuhr F., Busch M., Einhäupl K.M. Differences in medical and surgical therapy for stroke prevention between leading experts in North America and western Europe. Stroke. 29:1998;339-345.
8. Goldstein L.B., Bonito A.J., Matchar D.B., Duncan P.W., DeFriese G.H., Odone E.Z., Paul J.E., Akin D.R., Samaspirin G.P. US national survey of physician practices for secondary and tertiary prevention of ischemic stroke. Stroke. 26:1995;1607-1615.
9. Helgason C.M., Tortorice K.L., Winkler S.R., Penney D.W., Schuler J.J., McClelland T.J., Brace L.D. Aspirin response and failure in cerebral infarction. Stroke. 24:1993;345-350.
10. Ackerman R.H., Newman K.L. Incomplete platelet effects in patients on aspirin compounds. (Abstract). Ann Neurol. 28:1990;224.
11. Akopov S.S., Grigorian G.S., Grabielian E.S. Dose-dependent aspirin hydrolysis and platelet aggregation in patients with atherosclerosis. J Clin Pharmacol. 32:1992;133-135.
12. Toghi H., Konno S., Tamura K., Kimura B., Kawano K. Effects of low to high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and protacyclin. Stroke. 23:1992;1400-1404.
13. O'Brien J.R., Etherington M.D. How much aspirin? Thromb Haemost. 64:1990;486.
14. Grotemeyer K.H., Scharafinski H.W., Husstedt I.W. Two-year follow-up of aspirin responder and aspirin nonresponder. A pilot-study including 180 post-stroke patients. Thromb Res. 71:1993;397-403.
15. Helgason C.M., Bolin K.M., Hoff J.A., Winkler S.R., Mangat A., Tortorice K.L., Brace L.D. Development of aspirin resistance in persons with previous ischemic stroke. Stroke. 25:1994;2331-2336.
16. Chamorro A., Vila N., Ascaso C., Saiz A., Montalvo J., Alonso P., Tolosa E. Early prediction of stroke severity. Role of the erythrocyte sedimentation rate. Stroke. 26:1995;573-576.
17. Born G.U.R. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature. 194:1962;927-929.
18. Dixon W.J., Brown M.B., Engelman L., Hill M.A., Jennrich R.I. BMDP statistical software manual. 1988;University of California Press, Berkeley, Los Angeles, CA.
19. Schrör K. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost. 23:1997;349-356.
20. Barnett H.J.M., Kaste M., Meldrum B.A., Eliasziw M. Aspirin dose in stroke prevention. Beautiful hypotheses slain by ugly facts. Stroke. 27:1996;588-592.
21. Taylor D.W., Barnet H.J.M., Haynes R.B., Ferguson G.G., Sackett D.L., Thorpe K.E., Simard D., Silver F.L., Hachinski V., Clagett G.P., Barnes R., Spence J.D. The ASA and carotid endarterectomy (ACE) trial. Lancet. 353:1999;2179-2184.
22. van Gijn J. Low doses of aspirin in stroke prevention. Lancet. 353:1999;2173-2174.
23. Hormes J.T., Austin J.H., James G., Smith D.B., Ens G., Solomons C., Filley C.M. Toward an optimal 'antiplatelet' dose of aspirin: preliminary observations. J Stroke Cerebrovasc Dis. 1:1991;27-35.